Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02111564 · ClinicalTrials.gov registry record · Phase 3
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 12,024
- Enrollment target
NCT02111564 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 12,024 participants.
The verdict
NCT02111564, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 12,024 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in high-risk, medically ill patients.
Interventions
- DRUG Placebo
- DRUG Rivaroxaban, 10 mg
- DRUG Rivaroxaban, 7.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,024 participants |
| Start Date | 2014-01-07 |
| Est. Completion | 2018-05-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02111564
The ClinicalTrials.gov registry entry for NCT02111564 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 12,024 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02111564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02111564 about?
NCT02111564 is a clinical study titled "A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients". The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in high-risk, medically ill patients.
What is the current status of trial NCT02111564?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 12,024 participants. The study started on 2014-01-07. Estimated completion is 2018-05-03.
What interventions are being tested in trial NCT02111564?
The interventions under investigation include: Placebo (DRUG), Rivaroxaban, 10 mg (DRUG), Rivaroxaban, 7.5 mg (DRUG).
Who is sponsoring clinical trial NCT02111564?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.